GEN-MKT-18-7897-A
Sep 13, 2018 | Blogs, Software, Technology | 0 comments
Advances in today’s technology have resulted in a need for higher and faster sample throughput, with increasing number of measured analytes per sample. The new SCIEX OS-MQ software breaks the routine and takes quantitation workflows to a new level.
Key features include:
Featuring a sleek, intuitive user interface combined with the peak integration algorithm, which allows you to automatically remove outliers from a calibration curve, and includes new tools for flagging and filtering results. Built from the software you already know and trust, these new features and more make data processing and review more streamlined and efficient than ever before, quick to learn and simple to master. The new SCIEX OS 1.4 was designed to support 21 CFR Part 11 Compliance, providing tools such as the incorporation of electronic audit trails, electronic signatures, and detailed security configurations. For those upgrading to SCIEX OS-MQ, a major benefit is the Explorer workspace, which provides the functionality for manual investigation of data similar to PeakView Software. With next-generation SCIEX OS-MQ software, you can be confident that you will achieve accurate and reliable results that address your laboratory requirements and increase overall laboratory productivity.
Read the latest tech note on how SCIEX is Improving Routine Quantitation Workflows in SCIEX OS-MQ.For more questions on upgrading, get in touch with a software specialist today >
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network